

# **Biomarkers**

## **Part II: Markets & Companies**

**By**

**Prof. K.K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor+ 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

**November 2018**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:     +4161-6924461**  
**Email:         info@pharmabiotech.ch**  
**Web site:      http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>21. Markets for Biomarkers .....</b>	<b>4</b>
<b>Introduction .....</b>	<b>4</b>
<b>Biomarker markets according to technologies/applications .....</b>	<b>4</b>
Markets for protein biomarkers .....	4
Biomarker market relevant to drug discovery and development .....	5
<i>Proteomic biomarker-based drug discovery .....</i>	<i>5</i>
Biomarker market relevant to epigenetics .....	5
Biomarker market relevant to bioinformatics .....	5
<b>Biomarker markets according to therapeutic areas .....</b>	<b>6</b>
Markets for cancer biomarkers.....	6
<b>Geographical distribution of biomarker markets.....</b>	<b>6</b>
<b>Drivers for the growth of markets for biomarkers .....</b>	<b>7</b>
<b>Biomarker patents .....</b>	<b>7</b>
Factors that enhance the value of biomarker IP .....	7
US policy on patenting relevant to biomarkers.....	8
<i>US legal decisions on gene patenting.....</i>	<i>9</i>
<b>Strategies for developing biomarker markets.....</b>	<b>10</b>
Utilization of biomarker research in academic laboratories.....	10
Biomarker discovery at pharmaceutical companies.....	11
Industrial-academic collaborations in biomarkers .....	11
<b>Future of biomarkers .....</b>	<b>12</b>
<b>Unfulfilled needs in biomarkers .....</b>	<b>12</b>
Challenges facing the biomarker industry.....	13
Application of biomarkers in healthcare.....	13
Applications of biomarkers beyond healthcare .....	13
<i>Combating bioterrorism .....</i>	<i>14</i>
<i>Biomarkers for monitoring human exposure to environmental toxins .....</i>	<i>14</i>
<b>22. Companies .....</b>	<b>16</b>
<b>Introduction .....</b>	<b>16</b>
<b>Top companies in biomarkers .....</b>	<b>24</b>
<b>Profiles of companies.....</b>	<b>25</b>
<b>Collaborations.....</b>	<b>380</b>

## Tables

Table 21-1: Biomarker markets according to technologies/applications 2016-2026 .....	4
Table 21-2: Biomarker markets according to therapeutic areas 2016-2026 .....	6
Table 21-3: Geographical distribution of biomarker markets 2016-2026 .....	6
Table 21-4: Factors driving the growth of biomarker industry .....	7
Table 22-1: Companies with focus on biomarkers .....	16
Table 22-2: Pharmaceutical and biotechnology companies involved in biomarkers .....	17
Table 22-3: Molecular diagnostic companies.....	18
Table 22-4: Proteomics, metabolomics, glycomics, and systems biology companies .....	19
Table 22-5: Pharmacogenomic/pharmacogenetic & personalized medicine companies .....	21
Table 22-6: Companies with biochips, biosensors and imaging technologies.....	22
Table 22-7: Nanobiotechnology companies .....	22
Table 22-8: Companies involved in drug discovery and development.....	22
Table 22-9: Bioinformatic companies involved in biomarkers.....	23
Table 22-10: Service, equipment and reagent supply companies .....	23
Table 22-11: Top biomarker companies.....	24
Table 13-12: Collaborations between companies.....	380

## Figures

Figure 21-1: Unfulfilled needs in biomarkers technologies and applications .....	12
--	----